Oxygen-less　dependent　Type　I　photosensitizers　(PSs)　have　emerged　as　a　crucial　strategy　for　enhancing　photodynamic　therapy　efficiency　in　treating　hypoxic　tumors.　However,　solid　tumors　have　normoxia　regions　situated　near　functional　blood　vessels　and　hypoxia　regions　in　their　interiors.　To　maximize　the　utilization　of　oxygen　within　solid　tumors,　herein　a　viable　donor　optimizing　approach　is　developed　to　enhance　both　Type　I&II　reactive　oxygen　species　generation　of　PSs.　At　the　same　mole　concentration,　one　optimized　PS　(named　DE)　generated　9　times　more　O-1(2)　than　commercial　Type　II　PS　Chlorin　e6　upon　white　light　irradiation　for　60　s.　Compared　to　the　commercial　Type　I　PS　Rose　Bengal,　center　dot　OH　generation　by　DE　is　2.9　times　more　under　the　hypoxia　condition.　With　its　optimized　Type　I&II　pathway　under　normoxia　and　hypoxia　conditions,　DE　is　proven　to　be　an　efficient　PS　for　solid　tumor　treatment,　offering　a　promising　approach　for　PS　development.